WO2018132867A1 - Dispositif inhalateur pour liquides inhalables - Google Patents

Dispositif inhalateur pour liquides inhalables Download PDF

Info

Publication number
WO2018132867A1
WO2018132867A1 PCT/AU2018/050025 AU2018050025W WO2018132867A1 WO 2018132867 A1 WO2018132867 A1 WO 2018132867A1 AU 2018050025 W AU2018050025 W AU 2018050025W WO 2018132867 A1 WO2018132867 A1 WO 2018132867A1
Authority
WO
WIPO (PCT)
Prior art keywords
vapour
inhaler device
vapour impermeable
sachet
patient
Prior art date
Application number
PCT/AU2018/050025
Other languages
English (en)
Inventor
Scott Cameron COURTNEY
Original Assignee
Medical Developments International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900141A external-priority patent/AU2017900141A0/en
Application filed by Medical Developments International Limited filed Critical Medical Developments International Limited
Priority to AU2018210671A priority Critical patent/AU2018210671A1/en
Priority to CN201880012484.8A priority patent/CN110300610A/zh
Publication of WO2018132867A1 publication Critical patent/WO2018132867A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0241—Anaesthetics; Analgesics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00—Methods of manufacture, assembly or production
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/06—Packaging for specific medical equipment

Definitions

  • the application relates to a product for the storage and/or administration of inhalable volatile liquids such as halogenated volatile liquids, to a patient.
  • the application also relates to a process for manufacturing the product and a method for the storage and/or administration of inhalable volatile liquids such as halogenated volatile liquids, to a patient.
  • active agents such as therapeutic agents or pharmaceutical agents
  • oral delivery in the form of tablets and capsules
  • nasal delivery in the form of sprays and liquid formulations for intravenous delivery.
  • the active agent may be administered by the oral inhalation route, alone or in combination with the intranasal route.
  • Suitable inhaler devices may include, for example, metered dose inhalers and dry powder inhalers. These types of oral inhalation devices typically require pressurised means to deliver the active agent to the desired site of action in the lungs.
  • liquids that contain active agents or that are themselves the active agent usually require transformation into an inhalable, respirational, form at the point of administration to be suitable for delivery by the inhalation route.
  • Transforming a liquid into an inhalable form requires delivery devices to include moving, mechanical, heating and/or electrical means which adds to the complexity of the design, manufacturing and end user costs, operability and/or patient use.
  • volatile liquids as active agents or comprising active agents.
  • One such example is halogenated volatile liquids.
  • Halogenated volatile liquids have been described as useful for inducing and/or maintaining anaesthesia (including amnesia, muscle paralysis, and/or sedation) and/or analgesia and may therefore be useful as anaesthetics and/or analgesics.
  • the anaesthetic properties of fluorinated compounds have been known since at least 1946 (Robbins, B.H. J Pharmacol Exp Tfter (1946) 86: 197-204).
  • Halogenated volatile liquids when used for general anaesthesia, may be delivered to a patient under positive pressure via a delivery system that includes a vaporizer and a flow of breathable carrier gas. More recently, halogenated volatile liquids have been formulated for use in local or regional anaesthesia and delivery via non-inhalation routes. Examples include formulation as: microdroplets for intradermal or intravenous injection (e.g.
  • aqueous solutions for intrathecal or epidural delivery e.g. WO2008/036858
  • swab, droplets, spray or aerosol for transmucosal delivery e.g. WO2010/025505
  • compositions suitable for formulation into a medical patch e.g.
  • compositions suitable for formulation as a solution, suspension, cream, paste, oil, lotion, gel, foam, hydrogel, ointment, liposome, emulsion, liquid crystal emulsion and nanoemulsions for topical, intrathecal, epidural, transdermal, topical, oral, intra-articular, mucosal, buccal, rectal, vaginal, intramuscular, intravesical and subcutaneous delivery (e.g. WO2008/070490, WO2009/094460, WO2010/129686); and stable and injectable liquid formulations
  • the main consideration(s) for the safe storage and handling of volatile liquids commonly include vapour pressure build up, the robustness of the container and the integrity of the container seal(s).
  • the chemical nature of the volatile liquid may also be important if the active agent is capable of permeating, solubilizing or otherwise reacting with the container material(s) upon storage.
  • a number of storage containers for halogenated volatile liquids have been described including: rigid polymeric containers as a replacement for glass vials, such as capped bottles large tanks, shipping containers (e.g. W01999/034762,
  • WO2013/149263, WO2015/034978 a container with a capped membrane for delivering a stored liquid anaesthetic to a vaporizer via a slotted tube
  • rigid polymeric and aluminium containers optionally coated with materials to impart or enhance vapour barrier characteristics or container inertness e.g. WO2002/022195,
  • WO2008/040062 describes a diverse number of inhaler device concepts that depend on complex constructions and moving parts for storing and/or delivering inhalable liquids and powdered solids into a user's mouth or nose.
  • the various devices described are adapted to hold one or two medicament containers in the form of pressurised canisters, ampoules, vials and plungers.
  • the devices are described as being activated by sliding an outer wall of the device in relation to an inner wall of the device to deliver the liquid medication from a medication container.
  • the device includes a moveable mouthpiece which deploys in order to open the air pathway.
  • the device is also described as including one or more one-way valves to provide a unidirectional air flow for one or both inhaled air and exhaled air (a series of one-way valves to direct the flow of inhaled and exhaled air has also been generally described in WO2007/033400 which is an incorporation by reference of the device described in WO1997/00371 1).
  • the devices of WO2008/040062 are claimed as being capable of releasing the medication by punching means namely two punches to perforate the two frangible ends respectively of a medication container having frangible ends, although various other means are generally described including: pressurised means (e.g. by a pressurised canister); frangible means (e.g. by rupturing an ampoule with a striker or by punching a frangible membrane or seal of a vial with punch means); crushable means (e.g. by crushing a vial with a plunger); dislodging means (e.g. by dislodging an unscrewed cap from a vial); and plunging means (e.g. by plunging the medication from the plunger barrel).
  • pressurised means e.g. by a pressurised canister
  • frangible means e.g. by rupturing an ampoule with a striker or by punching a frangible membrane or seal of a vial with punch means
  • inhalable liquids such as halogenated volatile liquids require an effective air chamber into which the vapour may evaporate and allow an effective airflow through the air/vapour chamber for delivery to a patient.
  • embodiments such as those described in, for example, Figures 48A, 48B, 48C, 49A, 49B, 50A, 50B, 51 A, 51 B, 56A, 56B, 57, 58A, 58B, 58C and 58D of WO2008/040062, would not be expected to work in practice as the evaporative means (or wick) is prevented from being effectively exposed to the released liquid by the walls of the liquid storage container itself.
  • the present invention provides a new product for the storage and administration of inhalable liquids as a vapour to a patient offering one or more advantages or improvements over known inhaler products, in particular known inhaler products for the storage and administration of halogenated volatile liquids such as methoxyflurane for use as an analgesic.
  • the product is capable of storing and administering an inhalable liquid, such as a halogenated volatile liquid, as a vapour by providing an inhaler device comprising a passive evaporation support material located within the inhaler device and pre-loaded with the liquid wherein the inhaler device is stored within a vapour impermeable sachet to sealingly store the inhalable liquid as it forms a partial vapour upon storage within the inhaler device.
  • an inhalable liquid such as a halogenated volatile liquid
  • the product is considered to offer one or more advantages, for example, an easy to use, pre-loaded (i.e. primed for use) for rapid administration, readily portable inhaler device for delivering an inhalable liquid (such as methoxyflurane) to a patient.
  • advantages of the product may also include reductions in manufacturing costs, shipping, packaging, storage and disposal costs as well as material wastage, by avoiding the need to store the liquid in a separately manufactured container.
  • the product is considered to obviate the need for a separate packaging process and storage container for an inhalable liquid to be delivered to a patient via an inhaler device.
  • the product is therefore considered to provide an advantage in particular for the storage and delivery of methoxyflurane which currently involves packaging and storage of the
  • methoxyflurane as a liquid in a separate container (glass vial with screw-cap lid) prior to the administrator (e.g. paramedic) or user manually loading the liquid (by opening the glass vial and carefully pouring its contents i.e. the dosing amount) into the device (onto the wick) when the device is required to deliver the drug to the patient (for analgesia).
  • the product and method according to the present application allows for immediate availability of the required dosing amount of methoxyflurane to the patient once the vapour impermeable sachet is opened.
  • a product for the storage and administration of a dosing amount of an inhalable liquid to a patient comprising:
  • the inhaler device is sealed within the vapour impermeable sachet and further wherein the vapour impermeable sachet is adapted to exclude or minimise excess air to sealingly store the dosing amount within the inhaler device as it forms a (partial) vapour upon storage of the product such that when the vapour impermeable sachet is opened, the dosing amount is available for administration to the patient as a vapour from the inhaler device.
  • an inhaler device comprising an external housing and an internally located passive evaporation support material
  • the excess air is excluded or minimised to sealingly store the dosing amount within the inhaler device as it forms a (partial) vapour upon storage of the product such that when the vapour impermeable sachet is opened, the dosing amount is available for administration to the patient as a vapour from the inhaler device.
  • step (5) may, in practice, occur
  • the vapour impermeable material for use in the process according to the second aspect may be a vapour impermeable film or foil and may, prior to sealing to enclose the device comprising the pre-loaded inhalable liquid within the vapour impermeable sachet for storage, be provided in the form of for example: (a) a sachet with an opening to allow for insertion of the inhaler thereinto prior to sealing the device within the material (i.e. in the form of the vapour impermeable sachet); or (b) one or more (for example, two (2)) sheets to surround the inhaler or to place the inhaler there-between i.e. from which the vapour impermeable sachet is formed upon sealing).
  • a method for the storage and administration of a dosing amount of an inhalable liquid to a patient comprising: (1) sealingly storing an inhaler device within a vapour impermeable sachet wherein the inhaler device comprises a passive evaporation support material that is located internally within an external housing of the device and is pre-loaded with the dosing amount of the liquid;
  • vapour impermeable sachet is adapted to exclude or minimise excess air to sealingly store the dosing amount within the inhaler device as it forms a (partial) vapour upon storage such that when the vapour impermeable sachet is opened, the dosing amount is available for administration to the patient as a vapour from the inhaler device.
  • "excess air” is considered to be an unwanted or undesirable volume of air that is (or may be) present intermediate the external housing of the inhaler device and internal surface of the vapour impermeable sachet (for example any air pockets that are external to the inhaler device but captured within the sachet) into which any (partial) vapour that may form as a result of the vapour (or gas) - liquid equilibrium that may occur upon storage of the product, may escape, thereby resulting in an unwanted or undesirable loss or reduction in the dosing amount from the inhaler device and hence available for administration to the patient when the sachet is opened to access the inhaler device for use.
  • the vapour impermeable sachet is adapted to exclude or minimise excess air to prevent a loss or reduction of the dosing amount from within the inhaler device into the excess air volume as a vapour during storage.
  • the vapour impermeable material is capable of being shrink-wrapped to sealingly store the dosing amount as a (partial) vapour within the inhaler device.
  • the vapour impermeable material is capable of being heat-sealed to sealingly store the dosing amount as a (partial) vapour within the inhaler device.
  • the vapour impermeable material is capable of being shrink-wrapped to sealingly store the dosing amount as a (partial) vapour within the inhaler device.
  • impermeable material is capable of being ultrasonically welded to sealingly store the dosing amount as a (partial) vapour within the inhaler device.
  • the vapour impermeable material is a vapour impermeable film or foil.
  • the inhalable liquid is a halogenated volatile liquid.
  • the halogenated volatile liquid is selected from the group consisting of halothane (2-bromo-2-chloro-1 , 1 , 1-trifluoroethane), sevoflurane (fluoromethyl-2,2,2-trifluoro-1-(trifluroromethyl)ethyl ether), desflurane (2- difluoromethyl-1 ,2,2,2-tetrafluoroethrylether), isoflurane (1-chloro-2,2,2- trifluoroethyldifluoromethyl ether), enflurane (2-chloro-1 , 1 ,2-trifluoroethyldifluoromethyl ether) and methoxyflurane (2,2-dichloro-1 , 1-difluoroethylmethyl ether).
  • the inhalable liquid is methoxyflurane
  • FIGURE 1 shows a prior art inhaler device, referred to as the Green WhistleTM inhaler device (Medical Developments International Limited) that is currently used to administer
  • FIGURE 2 shows a product according to an embodiment of the invention comprising an inhaler device sealingly stored within a vapour impermeable sachet for storage (Figure 2A); opening the vapour impermeable sachet by tearing ( Figure 2B); and access to the inhaler device from the opened vapour impermeable sachet for use ( Figure 2C).
  • FIGURE 3 shows a top view of a product according to an embodiment of the invention comprising an inhaler device sealingly stored within a vapour impermeable sachet (Figure 3A); a rear- (or front-) perspective view along cross-sectional line A-A ( Figure 3B); and a side profile view (Figure 3C).
  • FIGURE 4 shows a cross-sectional view of an inhaler device (along its length) for use in a product or a method according to an embodiment of the invention to illustrate use of the product by the patient in administration mode, i.e., inhalation of the inhalable liquid as a vapour from within the inhaler device by the patient in the direction of the arrows shown following opening of and removal of the inhaler device from the vapour impermeable sachet.
  • FIGURE 5 presents the stability (storage) performance results under accelerated conditions of a product according to an embodiment of the invention.
  • FIGURE 6 presents the comparative drug delivery (administration) performance results of a product according to an embodiment of the invention and the current Green WhistleTM inhaler device of Figure 1 (without the 'AC chamber).
  • Inhaler devices that are useful for administering inhalable liquids may be generally considered to operate by either passive or active means in order to deliver the active agent(s) to a patient.
  • Inhaler devices with active means may include pressurized, moving, mechanical, heating and/or electrical means to, for example, nebulise, vaporize and/or generally deliver the active agent(s).
  • inhaler devices with passive means rely solely on the vaporisation or evaporation of the active agent(s) at ambient conditions and respiration of the patient to deliver the active agent(s).
  • the AnalgizerTM inhaler device (Abbott Laboratories Corporation) is an example of a device that operates by passive means to deliver an inhalable liquid.
  • the AnalgizerTM was a registered, now lapsed, trademark in respect of an inhaler for the supervised self-administration of inhalation anaesthesia and was first used in 1968.
  • the AnalgizerTM was a very simple device that consisted of a white cylindrical polyethylene open-ended tube having a mouthpiece and an absorbent wick of polypropylene which was tightly rolled into a 'Swiss-roll' shape, i.e. cross-sectional view.
  • the Green WhistleTM inhaler device (Medical Developments International Limited) was subsequently developed during the 1990s and has since been used in Australia for the delivery of Penthrox®/TM (methoxyflurane ) as an analgesic (1.5mL or 3mL, storage brown glass vial container with screw cap).
  • Penthrox®/TM methoxyflurane
  • an analgesic 1.5mL or 3mL, storage brown glass vial container with screw cap.
  • the Green WhistleTM device includes certain functional improvements such as the inclusion of a one-way valve at the base end to prevent drug vapour loss from the device upon patient exhalation and an activated carbon ('AC') chamber designed to be externally fit into a dilution hole in the mouth piece to filter exhaled drug vapours.
  • 'AC' activated carbon
  • Additional design modifications to the base end included the introduction of cap lugs to assist removal of the cap from the glass vial used to store the drug dose to be delivered, a dome to facilitate the spread of the poured liquid onto the 'S-shaped' wick circumference (i.e. cross-sectional view) or, in the alternative to a dome, an inlet nipple to allow for the attachment of a breathable gas line to direct the gas through the device.
  • the Green WhistleTM device is designed for single patient use.
  • Methoxyflurane (Penthrox®/TM, Medical Developments International Limited) offers a non-narcotic, i.e. non-opioid analgesic alternative to common analgesics such as morphine and fentanyl. Methoxyflurane also presents an alternative to analgesics which are administered in oral tablet form or intravenously to a patient and may therefore be particularly useful when rapid pain relief is required in clinical, surgical (e.g. pre- and postoperative) and/or emergency settings (e.g. emergency department and triage management as well as by first-responders such as paramedics and search and rescue teams).
  • surgical e.g. pre- and postoperative
  • emergency settings e.g. emergency department and triage management as well as by first-responders such as paramedics and search and rescue teams.
  • the Green WhistleTM device is shown in Figure 1 and is currently the only device that is commercially available to administer methoxyflurane.
  • the administrator is required to hold the methoxyflurane bottle upright to use the base of the inhaler to loosen the bottle cap and then to remove the cap by hand before tilting the inhaler to a 45° angle and pouring the contents of the bottle into the base while rotating the device.
  • An AC-chamber may be optionally fitted externally to the device either beforehand or afterwards. While the device is effective, the number of steps and separate components may present handling difficulties for the administrator or self-administrator including the potential for a reduction in the dosing amount caused by spillage or incorrect loading, for example, in high-stress and/or emergency settings.
  • the present invention provides a new product for the storage and administration of inhalable liquids as a vapour to a patient offering one or more advantages or improvements over known inhalers, in particular known inhalers for the delivery of halogenated volatile liquids such as methoxyflurane for use as an analgesic.
  • the product is capable of both storing and administering an inhalable liquid, such as a halogenated volatile liquid, as a vapour by providing an inhaler device comprising a passive evaporation support material located within the inhaler device and pre-loaded with the required dosing amount of the liquid wherein the inhaler device is stored within a vapour impermeable sachet to sealingly store the dosing amount as it forms a (partial) vapour upon storage within the inhaler device.
  • an inhalable liquid such as a halogenated volatile liquid
  • the product comprising the inhaler device sealingly stored within a vapour impermeable sachet, functions as a sealed storage container for the dosing amount of inhalable liquid (and its vapour) so that the device is primed and ready for immediate delivery of the dosing amount of drug in (partial) vapour form to the patient upon opening the sachet.
  • the vapour impermeable sachet is opened to access the inhaler device sealingly stored therein and remove therefrom for administration of the dosing amount of drug in (partial) vapour form to the patient, that is to allow air to be drawn into the device (for example as illustrated in Figure 4) upon inhalation by the patient through the device when required for use.
  • the vapour impermeable sachet is adapted to exclude or minimise any excess air (that is, excess air intermediate the external housing of the inhaler device and internal surface of the vapour impermeable sachet, for example, any air pockets that may form within the vapour impermeable sachet that are external to the inhaler device) during the process of sealingly storing the device within the vapour impermeable sachet.
  • excess air that is, excess air intermediate the external housing of the inhaler device and internal surface of the vapour impermeable sachet, for example, any air pockets that may form within the vapour impermeable sachet that are external to the inhaler device
  • the exclusion or minimisation of the presence of excess air is considered to offer the advantage of preventing any loss or reduction in the stored vapour from within the inhaler device during storage and hence dosing amount available for delivery to the patient when the sachet is opened to access the inhaler and allow for administration of the inhalable liquid as a vapour from the inhaler to the patient.
  • the product is therefore adapted for storing the inhalable liquid as a (partial) vapour within the device and administering the dosing amount in the form of the stored (partial) vapour upon opening the vapour impermeable sachet to access the device and subsequently as a vapour from passive release of the liquid from the passive evaporation support material during use of the device i.e. upon inhalation by a patient.
  • the inhalable liquid forms a (partial) vapour within the inhaler device such that the stored partial vapour is available (primed for use) for direct (immediate) administration to a patient upon opening the vapour impermeable sachet.
  • the relative amount of stored liquid to vapour in the inhaler device during storage will depend on the storage conditions (i.e. temperature and/or pressure dependent).
  • the vapour impermeable sachet When the inhaler device is required for use, the vapour impermeable sachet is opened and the device removed therefrom to allow for an air/vapour flow pathway through the device and an initial delivery of the stored partial vapour to the patient when the patient first inhales through a mouthpiece end of the device. Subsequent delivery of the dosing amount that is in liquid form may then occur as the liquid is released as a vapour from the passive evaporation support material during use of the device (i.e. inhalation of the released vapour by the patient).
  • the product is therefore considered to offer one or more advantages, for example, an easy to use, pre-loaded (i.e. primed for use) for rapid administration, readily portable inhaler which may also provide further reductions in manufacturing costs, shipping, packaging, storage and disposal costs as well as material wastage, by avoiding the need to store the liquid in a separately manufactured container.
  • 'Active agent' refers to therapeutic agents and non-therapeutic agents and compounds, formulations and compositions comprising them.
  • 'Alleviate', 'Alleviation' and variations thereof refers to relieving, lessening, reducing, ameliorating or an improvement in the symptom(s) and/or underlying cause(s) of a condition and/or disease in a patient.
  • 'Delivery dose' refers to the dose of inhalable liquid or active agent for administration to a patient.
  • 'Filter', 'Filtering' and variations thereof refers to the ability of a substance to absorb, adsorb, capture, trap, scavenge, scrub or partially or entirely remove the inhalable volatile liquid vapour from the exhaled breath of a patient upon exhalation.
  • Halogenated volatile liquids' refers to volatile liquids which (i) comprise at least one halogen atom selected from the group consisting of a chlorine (CI), bromine (Br), fluorine (F) and iodine (I) atoms, or (ii) comprise an active agent which comprises at least one halogen atom selected from the group consisting of a chlorine (CI), bromine (Br), fluorine (F) and iodine (I) atoms.
  • halogenated, particularly fluorinated, hydrocarbons and halogenated, particularly fluorinated, ethers may be preferred.
  • halogenated ethers may be particularly preferred and include but are not limited to, halothane (2-bromo-2-chloro-1 , 1 , 1-trifluoroethane), sevoflurane (fluoromethyl-2,2,2-trifluoro- 1-(trifluroromethyl)ethyl ether), desflurane (2-difluoromethyl-1 ,2,2,2-tetrafluoroethrylether), isoflurane (1-chloro-2,2,2-trifluoroethyldifluoromethyl ether), enflurane (2-chloro- 1 , 1 ,2- trifluoroethyldifluoromethyl ether) and methoxyflurane (2,2-dichloro-1 , 1-difluoroethylmethyl ether).
  • Inhalable liquid refers to liquids that comprise active agents or that are themselves the active agent and that are readily inhalable or capable of being or adapted to be inhaled by a patient.
  • inhalable volatile liquids particularly halogenated volatile liquids are preferred.
  • 'Inhalation', 'Inhalable' and variations thereof refers to the intake of, for example but not limited to air, breathable gases, inhalable liquids, by a patient and includes both oral and nasal inhalation. In some embodiments, oral inhalation is particularly preferred.
  • 'Patient' refers to both human and veterinary patients. In some embodiments, human patients may be particularly preferred. Reference to a patient will therefore be understood to mean the person or animal to whom the inhalable liquid is administered to and in the case of human patients, will be understood to include administration by self-administration.
  • 'Pharmaceutical agent' refers to a drug, or a compound, formulation or composition that comprises a drug, for the treatment of symptom(s) and/or underlying cause(s) of a condition and/or disease in a patient.
  • the term pharmaceutical agent may be used interchangeably with therapeutic agent or active agent.
  • 'Respiratory', 'Respirational' and variations thereof refers to the act of respiring, breathing, inhaling and exhaling, such as for example but not limited to air, breathable gases, inhalable liquids and active ingredients, by a patient.
  • Room temperature' refers to ambient temperatures which may be, for example, between 10°C to 40°C but more typically between 15°C to 30°C.
  • 'Therapeutic agent' refers to an active agent, or a compound, formulation or composition (including biological compounds, formulations and compositions) that comprises an active agent, that is capable of treating a patient or offers a therapeutic or medical benefit to a patient or that has or that requires regulatory and/or marketing approval for therapeutic use in a patient.
  • Therapeutic agents include pharmaceutical agents.
  • a 'Non- therapeutic agent' will be understood to mean an active agent which may not have or require regulatory and/or marketing approval for a therapeutic use such as, for example, smokeless tobacco products and electronic cigarettes, or does not have a recognised or identified therapeutic use but may be used by a patient for a non-therapeutic reason such as general health, wellbeing or physiological benefit such as, for example, nutraceutical products.
  • 'Treat', 'Treatment' and variations thereof refers to the alleviation, modulation, regulation or halting of the symptom(s) and/or underlying cause(s) of a condition and/or disease in a patient.
  • treatment may include preventative or prophylactic treatment.
  • Volatile liquids' refers to substances that predominantly exist in a liquid form but readily form vapours, evaporate or vaporize such that they partially exist in a vapour form under ambient conditions for example, at room temperature and at normal atmospheric pressures.
  • the present product comprises a passive evaporation support material pre-loaded with the inhalable liquid to provide a portable, ready-to-use, all-in-one, drug storage and delivery device.
  • the present product provides easy and rapid administration, in particular self-administration when rapid pain relief is required, for example, in emergency, non-hospital, isolated, outdoor environment, sporting, humanitarian aid and/or field operation environments.
  • the vapour impermeable sachet comprises a vapour impermeable material.
  • the vapour impermeable material is a vapour impermeable film.
  • Vapour impermeable films may be a single layer or a laminate film comprising at least one vapour impermeable layer.
  • the vapour impermeable material is a foil.
  • the vapour impermeable material is in the form of a sachet with an opening to allow for insertion of the inhaler device comprising the inhalable liquid thereinto prior to sealing the opening to enclose the device within the vapour impermeable sachet for storage.
  • vapour impermeable material is in the form of a single sheet to surround the inhaler device comprising the inhalable liquid therein prior to sealing the sheet to enclose the device within the vapour impermeable sachet for storage.
  • vapour impermeable material is in the form of two sheets to allow for placement of the inhaler device comprising the inhalable liquid there-between prior to sealing the sheets to enclose the device within the vapour impermeable sachet for storage.
  • vapour impermeable sachet may be formed (or sealed) from the vapour impermeable material by suitable sealing processes available to seal vapour impermeable materials (such as films or foils) and to further exclude or minimise excess air for the purpose(s) as described herein.
  • the vapour impermeable material is adapted to form the vapour impermeable sachet upon sealing by a suitable sealing process, such as is described herein.
  • the vapour impermeable sachet is formed (or sealed) such that a 'close- fit' around the external housing of the inhaler device is achieved to exclude or minimise excess air.
  • the inhaler device is sealed within the vapour impermeable sachet such that a 'close-fit' between an external housing of the inhaler device and an internal surface of the vapour impermeable sachet is achieved to exclude or minimise the excess air.
  • Suitable sealing processes may include, for example, by a physical process (such as, for example, by shrink-wrapping or by welding, for example, thermal welding, ultrasonic welding) or by a chemical process (such as, for example, by adhesives).
  • the vapour impermeable material is adapted to form the vapour impermeable sachet upon sealing by a process selected from the group consisting of thermal welding, ultrasonic welding and shrink-wrapping wherein the process is adapted to exclude excess air.
  • the inhaler device is sealingly stored within the vapour impermeable sachet by a process selected from the group consisting of thermal welding, ultrasonic welding and shrink-wrapping wherein the process is adapted to exclude excess air.
  • the vapour impermeable sachet comprises a vapour impermeable material (such as a polymeric film or foil) that is suitable for shrink-wrapping.
  • the vapour impermeable sachet comprises a vapour impermeable material (such as a polymeric film or foil) that is suitable for thermal-weld sealing.
  • vapour impermeable sachet comprises a vapour impermeable material (such as a polymeric film or foil) that is suitable for ultrasonic-weld sealing.
  • the vapour impermeable sachet comprises a therompolymer.
  • the vapour impermeable sachet comprises a polymer selected from the group consisting of polyethylene terephthalate ('PET'), polypropylene (' ⁇ ') and
  • vapour impermeable sachet comprises polyethylene terephthalate ('PET'). In other embodiment the vapour impermeable sachet comprises polypropylene (' ⁇ '). In yet another embodiment the vapour impermeable sachet comprises polyethylene (' ⁇ ').
  • vapour impermeable films include but are not limited to polymeric films, metal foils (such as, for example, aluminium, nickel and alloys thereof) and combinations, including co-extruded polymeric films and/or foils such as laminate films, thereof.
  • the vapour impermeable film is a single layer selected from a polymeric film or a metal foil.
  • the vapour impermeable film is a laminate film comprising two or more layers selected from a polymeric film, a metal foil and combinations, including co- extruded polymeric films and/or foils, thereof.
  • the laminate film may comprise a weldable layer made from a suitable weldable foil or polymeric film such as, for example, LLDPE.
  • a weldable layer may assist with sealing the layers of a laminate together and/or sealing a vapour impermeable film comprising a weldable layer to the device.
  • Processes suitable for welding include thermal and ultrasonic welding.
  • the laminate film may comprise an adhesive layer including a peelable adhesive layer.
  • the polymeric film has a MVTR of less than 100 g/m 2 /24h, preferably less than 50 g/m 2 /24h.
  • the polymeric film comprises a polymer selected from the group consisting of a polyolefin, a polymeric phthalate, a fluorinated polymer, a polyester, a nylon, a polyvinyl, a polysulfone, a natural polymer and combinations, including co-extruded polymers thereof including biaxially orientated polymers such as, for example, biaxially orientated polypropylene (BOPP).
  • BOPP biaxially orientated polypropylene
  • the polymeric film comprises a polymer selected from the group consisting of PP, PE, LDPE, LLDPE, HDPE, BOPP, 4-methylpentene, polymethylpentene polycyclomethylpentene, PEN, PET, PETP, PEI, PBT, PTT, PCT, Kel-F, PTFE, cellulose acetate, POM, PETG, PCTG, PCTA, nylon, PVA, EVOH, starch, cellulose, proteins and combinations, including co-extruded polymers, thereof.
  • the vapour impermeable film comprises PET.
  • the vapour impermeable film comprises PET and a metal foil layer, preferably an aluminium foil layer.
  • the vapour impermeable film comprises metalised PET (Met PET).
  • the vapour impermeable film comprises a co-extruded polymer layer adhered to a metalised PET layer adhered to an externally peelable LLDPE layer.
  • the co-extruded polymer layer is a biaxially orientated polymer, preferably BOPP.
  • the vapour impermeable film comprises a layer of BOPP adhered to a metalised PET layer adhered to an externally peelable LLDPE layer.
  • the vapour impermeable sachet optionally comprises an introduced point of weakness to aid with opening the sachet (for example by tearing, perforating or ripping) to access the device when the device is required for use. Suitable means to introduce a point of weakness into the vapour impermeable sachet will be familiar to those in the art and may include, for example, a thin-ness (i.e. thinner section of material), perforations or a cut-out section.
  • the vapour impermeable sachet comprising the inhaler device (Figure 2A) is opened by tearing ( Figure 2B) to access the inhaler device for use ( Figure 2C).
  • the vapour impermeable sachet (5) comprises a point of weakness (6) to assist opening and is formed (or sealed) such that a 'close-fit' around the external housing (7) of the inhaler device (8) is achieved to exclude or minimise excess air.
  • a cross-sectional rear-(or front-) perspective view of the product of Figure 3A along A-A is shown in Figure 3B and a side profile view of the product is further provided in Figure 3C.
  • the passive evaporation support material stored within the inhaler device is adapted to form a single longitudinal airflow/vapour pathway though the device when the vapour impermeable sachet is opened.
  • the passive evaporation support material is adapted to form at least two independent longitudinal airflow/vapour pathways though the inhaler device when the vapour impermeable sachet is opened.
  • the passive evaporation support material is adapted to form three or more independent longitudinal airflow/vapour pathways though the inhaler device when the vapour impermeable sachet is opened.
  • the passive evaporation support material stored within the inhaler device is adapted to provide a single longitudinal airflow/vapour pathway though the inhaler device when the vapour impermeable sachet is opened and in one embodiment is planar.
  • the passive evaporation support material is adapted to form at least two independent longitudinal airflow/vapour pathways, three or more independent longitudinal airflow/vapour pathways, through the inhaler device when the vapour impermeable sachet is opened. Numerous examples of cross-sectional shapes which are capable of forming at least two, three or more independent longitudinal airflow/vapour pathways may be envisaged, some of which follow.
  • the two, three or more independent longitudinal airflow/vapour pathways may be formed by the passive evaporation support material adopting a cross-sectional shape selected from a letter of the alphabet or a single digit number such as, for example although not limited to, an A-shape, B-shape, S-shape, Z-shape, figure-2 , figure-5 and figure-8 which are capable of forming at least two independent airflow/vapour pathways, and a K-shape, M-shape, V-shape, W-shape, X- shape, Y-shape and figure-3 which are capable of forming three or more independent longitudinal airflow/vapour pathways through the inhaler device when the vapour
  • the passive evaporation support material is adapted to provide three or more independent longitudinal airflow/vapour pathways.
  • the pathways may be formed as independent conduits through the passive evaporation support material itself or the pathways may be formed by the evaporative means making contact with an internal surface of the vapour chamber.
  • the passive evaporation support material comprises three or more longitudinal conduits wherein the conduits are formed within the passive evaporation support material or are formed by the passive evaporation support material together with an internal surface of the inhaler device or a combination thereof when the vapour impermeable sachet is opened.
  • the passive evaporation support material may be made from any material that is suitable for absorbing the inhalable liquid and passively releasing it as a vapour.
  • Materials which have wicking properties may be suitable passive evaporation support material for use in the present product.
  • Wicking properties will generally be understood to include the ability of a material to facilitate or enhance the rate of evaporation or vaporisation of a liquid from its surface by distributing the liquid, whether by drawing, spreading, pulling or otherwise, throughout the material from its initial point of contact and/or as it evaporates from an exposed surface area of the material.
  • the passive evaporation support material is a wicking material.
  • the wicking material is a wicking felt or a porous polymeric material.
  • the wicking material is a polypropylene wicking felt.
  • the inhaler device is the Green Whistle inhaler device (without the externally fitted 'AC'-chamber).
  • the 'AC'-chamber may optionally be fitted for administration of the inhalable liquid (methoxyflurane) to the patient in the usual manner following opening of and removal of the device from the vapour impermeable sachet.
  • inhaler devices that may be suitable for use in the present product, process and/or method of the invention may include, for example, a device described in international application numbers, PCT/AU2016/050636, PCT/AU2016/050637, PCT/AU2016/050638 or PCT/AU2016/050639.
  • the inhaler device will typically comprise an external housing and an internal air chamber within which the passive evaporation support material pre-loaded with inhalable liquid is located and into which the (partial) vapour forms upon storage of the product.
  • the external housing will typically comprise a mouthpiece end with a mouthpiece (or vapour inhalation) opening which is adapted to allow the patient to inhale the vapour from the internal air chamber.
  • the external housing will also typically comprise an air inlet to allow for the intake of air into the internal air chamber and formation of an air/vapour pathway through the inhaler device, more particularly through the internal air chamber comprising the vapour, to allow for the delivery of the vapour to the patient upon inhalation when the inhaler is in use (i.e. following opening of and removal of the device from the vapour impermeable sachet).
  • the external housing further comprises:
  • a mouthpiece end with a mouthpiece (or vapour inhalation) opening adapted to allow the patient to inhale the dosing amount as a vapour from the internal air chamber
  • an air inlet to allow for the intake of air into the internal air chamber and formation of an air/vapour pathway through the inhaler device to allow for the delivery of the vapour to the patient upon inhalation when the inhaler is in use.
  • the external housing generally adopts substantially the same cross- sectional shape along its length.
  • the cross-sectional shape of the external housing is selected from circular, semi-circular, elliptical, semi-elliptical, oval, ovoidal, square, rectangular, trapezoidal, triangular and combinations thereof. Shapes having square corners may also be replaced with rounded corners, for example, a rectangle having a square corner replaced by a rounded one may be referred to as a rounded rectangular shape.
  • the cross-sectional shape of the elongated housing is selected from cylindrical, rectangular, rounded rectangular, trapezoidal and rounded trapezoidal.
  • the cross-sectional shape of the mouthpiece end may be the same or different to the rest of the elongated housing.
  • the mouthpiece end is tapered towards the vapour inhalation opening.
  • the cross-sectional shape of the vapour inhalation opening is adapted to fit a conventional aerosol or nebuliser face mask.
  • the inhaler device is as illustrated in Figure 4.
  • the cross-sectional view presented in Figure 4 shows the inhaler device (9) in use by a patient.
  • the passive evaporation support material pre-loaded with the inhalable liquid (10) is positioned within an air intake chamber (1 1) of the device.
  • the air intake chamber comprises an air inlet opening (12) which enables air/vapour to flow through the air intake chamber (external air flows into the device via the air inlet opening and across the exposed surface(s) of the passive evaporation support material) and into the mouthpiece chamber (13) once the vapour impermeable sachet is opened to enable delivery of the vapour that is released from the passive evaporation support material to the patient when the patient inhales through mouthpiece opening (14).
  • the direction of the air/vapour pathway upon inhalation by the patient is illustrated by the arrow (15).
  • the inhaler devices for use in the product or method may be made from various materials. However, suitable material(s) may be selected by considering whether they are chemically inert, stable and impervious with reference to the inhalable liquid to be stored and/or delivered. Material(s) may also be selected based on their suitability for medical device applications such as by reference to whether they meet approved standards for medical- grade human use by a regulatory authority like the FDA.
  • the inhaler device examples include but are not limited to polymers (including homopolymers and heteropolymers i.e. co-polymers), composites (including nanocomposites), metals (including alloys thereof) and combinations thereof.
  • the device is made from polymers (including homopolymers and heteropolymers i.e. co-polymers), composites (including nanocomposites such as polymers in combination with clay), metals (including aluminium and alloys thereof) and combinations thereof.
  • the device is optionally internally lined or coated with one or more material(s) selected from the group consisting polymers (including homopolymers and heteropolymers i.e. co-polymers), composites (including
  • nanocomposites such as polymers in combination with clay), metals (including aluminium, nickel and alloys thereof for example, stainless steel), oxides (including aluminium oxides, silicon oxides), resins (including epoxyphenolic resins and ionomeric resins such as
  • Polymers are particularly suited to large scale manufacturing of inhaler devices and the polymeric films described herein, in particular the inhaler device and the vapour
  • impermeable film by injection moulding, blow moulding and extrusion processes. They may also be suitable for manufacturing the inhaler device on a smaller scale by 3D printing techniques. Further, polymers may be recycled following disposal of the product.
  • polymers for use in making the inhaler device and polymeric films described herein may include but are not limited to the following polymers and combinations (including co-extruded polymers) thereof: polyolefins such as polypropylene (' ⁇ '), polyethylene (' ⁇ ') including low density ('LDPE'), linear low density ('LLDPE') and high density polyethylene ('HDPE'), biaxially orientated polypropylene (' ⁇ '), 4-methylpentene, polymethylpentene, polycyclomethylpentene; polymeric phthalates such as polyethylene naphthalates ('PEN'), polyethylene terephthalate ('PET') (also known as ('PETE')), polyethylene terephthalate polyester (' ⁇ '), polyethylene isophthalate (' ⁇ '), polybutylene terephthalate (' ⁇ '), polytrimethylene terephthalate (' ⁇ '), polycyclohexylenedimethylene terephthalate ('PCT'); fluorinated
  • polytetrafluoroethylene 'PTFE'
  • terephthalate/isophthalic acid 'PCTA'
  • nylons including amorphous nylon
  • polyvinyls including polyvinyl alcohol ('PVA') and ethylene vinyl alcohol ('EVOH')
  • polysulfones including polyethersulfone ('PES')
  • natural polymers including starch, cellulose and proteins.
  • Suitable polymers may also include polymers with a moisture vapour transmission rate ('MVTR', also known as water vapour transmission rate 'WVTR') of less than
  • the device is made from one or more polymers wherein the device further comprises an optional internal lining or coating with one or more material(s) selected from the group consisting polymers (including homopolymers and heteropolymers (also known as co-polymers) and combinations thereof including co-extruded polymers), composites (including nanocomposites such as polymers in combination with clay), metals (including aluminium, nickel and alloys thereof), oxides (including aluminium oxides, silicon oxides), spray coatings, resins (including epoxyphenolic resins and ionomeric resins such as Surlyn®, trademark of DuPont), lacquers and enamels.
  • material(s) selected from the group consisting polymers (including homopolymers and heteropolymers (also known as co-polymers) and combinations thereof including co-extruded polymers), composites (including nanocomposites such as polymers in combination with clay), metals (including aluminium, nickel and alloys thereof), oxides (including aluminium oxides, silicon oxides), spray coatings, resins
  • the polymer is selected from a polyolefin, a polymeric phthalate, a fluorinated polymer, a polyester, a nylon, a polyvinyl, a polysulfone, a natural polymer and combinations, including co-extruded polymers thereof.
  • the polymer has a MVTR of less than 100 g/m 2 /24h, preferably less than 50 g/m 2 /24h.
  • the polyolefin is selected from the group consisting of PP, PE, LDPE, LLDPE, HDPE, 4- methylpentene, polymethylpentene, polycyclomethylpentene and combinations, including co- extruded polymers thereof such as BOPP.
  • the polymeric phthalate is selected from the group consisting of PEN, PET, PETP, PEI, PBT, PTT, PCT and
  • the fluorinated polymer is selected from Kel-F, PTFE and combinations, including co-extruded polymers thereof.
  • the polyester is selected from the group consisting of cellulose acetate, POM and polyesters containing a terephthalate ester group including PETG, PCTG, PCTA and combinations , including co-extruded polymers, thereof.
  • the nylon is an amorphous nylon.
  • the polyvinyl is selected from PVA, EVOH and combinations, including co-extruded polymers, thereof.
  • the polysulfone is PES.
  • the natural polymer is selected from the group consisting of starch, cellulose, proteins and combinations, including co-extruded polymers, thereof.
  • the device is made from a single polymer selected from the group consisting of PP, PE, LDPE, LLDPE, HDPE, BOPP, 4-methylpentene, polymethylpentene polycyclomethylpentene, PEN, PET, PETP, PEI, PBT, PTT, PCT, Kel-F, PTFE, cellulose acetate, POM, PETG, PCTG, PCTA, nylon, PVA, EVOH, starch, cellulose, proteins and combinations, including co-extruded polymers, thereof.
  • the device is made from two or more polymers selected from the group consisting of PP, PE, LDPE, LLDPE, HDPE, 4-methylpentene, polymethylpentene polycyclomethylpentene, PEN, PET, PETP, PEI, PBT, PTT, PCT, Kel-F, PTFE, cellulose acetate, POM, PETG, PCTG, PCTA, nylon, PVA, EVOH, starch, cellulose, proteins and combinations, including co-extruded polymers, thereof.
  • the device is made from a polymer selected from the group consisting of HDPE, PET and combinations thereof.
  • the device comprises PET.
  • the present product will be particularly useful for storing and/or administering halogenated volatile liquids.
  • the product more particularly the inhaler device and/or the vapour impermeable sachet is made from one or more materials that are compatible with the storage and/or delivery of halogenated volatile liquids to a patient, in particular methoxyflurane for use as an analgesic.
  • the present product is considered to be particularly useful for storing and administering a halogenated volatile liquid, particularly methoxyflurane for use as an analgesic.
  • the product comprises a passive evaporation support material preloaded with a halogenated volatile liquid.
  • the halogenated volatile liquid is selected from the group consisting of halothane (2-bromo-2-chloro-1 , 1 , 1- trifluoroethane), sevoflurane (fluoromethyl-2,2,2-trifluoro-1-(trifluroromethyl)ethyl ether), desflurane (2-difluoromethyl-1 ,2,2,2-tetrafluoroethrylether), isoflurane (1-chloro-2,2,2- trifluoroethyldifluoromethyl ether), enflurane (2-chloro-1 , 1 ,2-trifluoroethyldifluoromethyl ether) and methoxyflurane (2,2-dichloro-1 , 1-difluoroethylmethyl ether).
  • the inhalable liquid is methoxyflurane for use as an analgesic.
  • Suitable dosing amounts of inhalable liquid for administration to a patient by the present product may be determined by reference to, for example, regulatory approved dosage amounts.
  • Suitable dosing amounts of methoxyflurane for use as an analgesic will typically be less than 15ml_ and preferably less than 12ml_ and selected from the group consisting of 0.5ml_, 1 ml_, 1.5ml_, 2ml_, 2.5ml_, 3ml_, 3.5ml_, 4ml_, 4.5ml_, 5ml_, 5.5ml_, 6ml_, 6.5ml_, 7ml_, 7.5ml_, 8ml_, 8.5ml_, 9ml_, 9.5ml_, 10ml_, 10.5ml_, 1 1 ml_, 11.5ml_ and 12ml_.
  • the dosing amount of methoxyflurane for administration by the present product is selected from the group consisting of 1.5ml_, 3ml
  • FIG 1 shows the prior art Green WhistleTM inhaler device (1) (Medical Developments International Limited) which is currently used in Australia for the delivery of Penthrox®/TM (methoxyflurane) as an analgesic (1.5ml_ or 3ml_, storage brown glass vial container with screw cap).
  • Penthrox®/TM methoxyflurane
  • analgesic 1.5ml_ or 3ml_, storage brown glass vial container with screw cap.
  • the delivery dose of methoxyflurane is manually poured into the base end (3) of the device. After the dose is poured into the base end for deposition onto the evaporative means (not shown), the methoxyflurane evaporates so that the patient can self-administer the analgesic by inhaling the air/vapour mix through the mouthpiece (2).
  • any exhaled air/vapour mix will exit the device via the (optional) externally fitted chamber containing activated carbon 'AC-chamber' (4).
  • a prototype product according to an embodiment of the invention was assembled by sealing an inhaler device having an internally located polypropylene wick pre-loaded with a dosing amount of methoxyflurane, within a vapour impermeable sachet as follows:
  • Inhaler device A standard Green Whistle inhaler device (as shown in Figure 1) was preloaded with a dosing amount of methoxyflurane (i.e. by pouring the dosing amount, 3ml_, in the form of a liquid, onto the wick).
  • Vapour Impermeable Sachet The pre-loaded inhaler device was placed within a vapour impermeable polymeric film comprising PET and the vapour impermeable sachet was formed by heat-sealing the film around the external housing of the device to exclude or minimise excess air and sealingly store the dosing amount within the inhaler device so that it is primed for delivering the inhalable liquid as a vapour to the patient when the sachet is opened.
  • the stability of the product may be tested using accelerated storage conditions such as for example in an oven set at 60°C and sampled at time periods appropriate for marketing and/or regulatory approval.
  • Example 2 The stability of the product of Example 2 was tested using six (6) products and the initial mass of each product measured. The products were then held for twenty (20) days at 60°C being equivalent to twelve (12) months shelf-life. The results are presented in Figure 5 (for each product tested labelled "Product 1", “Product 2” etc. respectively). Four (4) out of the six (6) prototype products tested maintained their original (initial) mass. The loss in mass that was observed for the two (2) remaining devices was attributed to ineffective/incomplete sealing which resulted in the methoxyflurane escaping as a vapour from the device (and corresponding reduction in dosing amount).
  • an inhaler device to deliver methoxyflurane may be tested using a breath simulator system such as a pulmonary waveform generator system.
  • the devices were tested as follows.
  • the pulmonary waveform generator was set to "Adult" flow conditions (14 breaths per minute) and the concentration logging software and Datex Sensor commenced.
  • the polypropylene wick was pre-loaded with methoxyflurane (3ml_) to be delivered and the mouthpiece end of the device then inserted into the opening of the pulmonary waveform generator.
  • Concentration logging was commenced for the first minute for the first breaths concentration and then for the next 20 minutes for steady state testing.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un produit pour le stockage et/ou pour l'administration à un patient de liquides volatils inhalables tels que des liquides volatils halogénés. L'invention concerne également un procédé de fabrication du produit et un procédé de stockage et/ou d'administration à un patient de liquides volatils inhalables tels que des liquides volatils halogénés.
PCT/AU2018/050025 2017-01-18 2018-01-17 Dispositif inhalateur pour liquides inhalables WO2018132867A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018210671A AU2018210671A1 (en) 2017-01-18 2018-01-17 Inhaler device for inhalable liquids
CN201880012484.8A CN110300610A (zh) 2017-01-18 2018-01-17 用于可吸入液体的吸入器装置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017900141A AU2017900141A0 (en) 2017-01-18 Inhaler device for inhalable liquids
AU2017900141 2017-01-18

Publications (1)

Publication Number Publication Date
WO2018132867A1 true WO2018132867A1 (fr) 2018-07-26

Family

ID=62907508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2018/050025 WO2018132867A1 (fr) 2017-01-18 2018-01-17 Dispositif inhalateur pour liquides inhalables

Country Status (3)

Country Link
CN (1) CN110300610A (fr)
AU (1) AU2018210671A1 (fr)
WO (1) WO2018132867A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565071A (en) * 1968-09-19 1971-02-23 Abbott Lab Self-regulating therapeutic inhaler
US6315112B1 (en) * 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6325063B1 (en) * 1998-01-26 2001-12-04 George A. Volgyesi Breath-powered mist inhaler
US20100083963A1 (en) * 2004-09-24 2010-04-08 David Peter Wharton Medication holder
US20110017626A1 (en) * 2007-11-09 2011-01-27 Astrazeneca Ab. Dispensing Device Packaging
WO2017011865A1 (fr) * 2015-07-20 2017-01-26 Medical Developments International Limited Dispositif d'inhalateur pour liquides à inhaler

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217004A (en) * 1990-12-13 1993-06-08 Tenax Corporation Inhalation actuated dispensing apparatus
KR100620338B1 (ko) * 1998-03-16 2006-09-13 넥타르 테라퓨틱스 에어로졸형 활성 제제 전달 방법
CA2467035A1 (fr) * 2001-11-17 2003-05-30 Aventis Pharma Limited Agents d'adsorption et leurs utilisations
GB2390645A (en) * 2002-05-22 2004-01-14 Cambridge Consultants Drug delivery assembly

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565071A (en) * 1968-09-19 1971-02-23 Abbott Lab Self-regulating therapeutic inhaler
US6325063B1 (en) * 1998-01-26 2001-12-04 George A. Volgyesi Breath-powered mist inhaler
US6315112B1 (en) * 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US20100083963A1 (en) * 2004-09-24 2010-04-08 David Peter Wharton Medication holder
US20110017626A1 (en) * 2007-11-09 2011-01-27 Astrazeneca Ab. Dispensing Device Packaging
WO2017011865A1 (fr) * 2015-07-20 2017-01-26 Medical Developments International Limited Dispositif d'inhalateur pour liquides à inhaler

Also Published As

Publication number Publication date
AU2018210671A1 (en) 2019-08-08
CN110300610A (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
US11672925B2 (en) Inhaler device for inhalable liquids
US20210113786A1 (en) Inhaler device for inhalable liquids
US20210113803A1 (en) Inhaler device for inhalable liquids
AU2017325107B2 (en) Inhaler device for inhalable liquids
AU2016297678B2 (en) Inhaler device for inhalable liquids
WO2018132867A1 (fr) Dispositif inhalateur pour liquides inhalables

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18741357

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018210671

Country of ref document: AU

Date of ref document: 20180117

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 18741357

Country of ref document: EP

Kind code of ref document: A1